Onco-Inmunología Aplicada y Traslacional
O-I Traslacional
![Foto de Onco-Inmunología Aplicada y Traslacional](/img/uploaded/5e1e7ce08027cbcdc3493fed993191d0.jpg)
![Foto de Centro de Investigación Biomédica en Red de Cáncer](/img/noimage_org.png)
Centro de Investigación Biomédica en Red de Cáncer
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Cáncer (50)
2024
2023
-
CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects
Science advances, Vol. 9, Núm. 33, pp. eadf6692
-
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary
Cancer discovery, Vol. 13, Núm. 3, pp. 552-569
-
Druggable Targets in Cytokine Release Syndromes
Clinical Cancer Research, Vol. 29, Núm. 21, pp. 4320-4322
-
Facts and Hopes on Neutralization of Protumor Inflammatory Mediators in Cancer Immunotherapy
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 23, pp. 4711-4727
-
Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control
Journal for immunotherapy of cancer, Vol. 11, Núm. 1
-
Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity
Cancer immunology research, Vol. 11, Núm. 2, pp. 184-198
-
Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists
Molecular Therapy - Nucleic Acids, Vol. 33, pp. 668-682
-
Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer
EMBO Reports, Vol. 24, Núm. 8
-
mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy
Cell Reports Medicine, Vol. 4, Núm. 3
2022
-
A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β
Cancer Discovery, Vol. 12, Núm. 9, pp. 2140-2157
-
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Nature Cancer, Vol. 3, Núm. 6, pp. 665-680
-
Revisiting Intracavitary Immunotherapy of Cancer
Clinical Cancer Research, Vol. 28, Núm. 10, pp. 1993-1995
-
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Journal for immunotherapy of cancer, Vol. 10, Núm. 3
-
YES1 Is a Druggable Oncogenic Target in SCLC
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403
2021
-
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic
Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26
-
Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patients
Cytokine, Vol. 141
-
Consolidating radiotherapy with immunotherapy
Clinical Cancer Research, Vol. 27, Núm. 20
-
Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils
European Journal of Immunology, Vol. 51, Núm. 9, pp. 2274-2280
-
Genomic mapping of splicing-related genes identify amplifications in lsm1, clns1a, and ilf2 in luminal breast cancer
Cancers, Vol. 13, Núm. 16